CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status
December 03, 2020 11:54 ET | CVRx, Inc.
MINNEAPOLIS, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for...
FBI LOGO TM.png
Global Cardiovascular Devices Market to Rise at 6.4% CAGR and Reach USD 82.20 Billion by 2026; Rising Awareness and Increasing Demand for Cardiovascular Surgical Devices Will Promote Market Growth, says Fortune Business Insights™
November 26, 2020 05:17 ET | Fortune Business Insights
Pune, Nov. 26, 2020 (GLOBE NEWSWIRE) -- According to the report, the cardiovascular devices market size was USD 49.90 billion in 2018 and is projected to rise at a CAGR of 6.4% between 2019 and...
US Capital Global Securities Launches $10MM Convertible Preferred Stock Offering for Cardax, Inc.
November 24, 2020 16:58 ET | US Capital Global
San Francisco, California, Nov. 24, 2020 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an affiliate of US Capital Global, is offering to eligible investors an investment opportunity of up to...
CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts
November 18, 2020 14:56 ET | CVRx, Inc.
MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s...
InCarda Logo.png
InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020
November 13, 2020 10:00 ET | InCarda Therapeutics, Inc.
Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of...
InCarda Logo.png
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
October 21, 2020 08:05 ET | InCarda Therapeutics, Inc.
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for...
GRCK Logo.png
Grey Cloak Tech Inc. Releases Independent Report
October 20, 2020 08:30 ET | Grey Cloak Tech Inc.
LAS VEGAS, Oct. 20, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- Grey Cloak Tech Inc. (OTC: GRCK) (soon to be Healthy Extracts Inc. pending a corporate name change), a company engaged in proprietary...
fior-markets-logo.jpg
Global Surgical Sealants and Adhesives Market Is Expected to Reach USD 4.34 billion by 2027 : Fior Markets
September 17, 2020 04:00 ET | Fior Markets
Newark, NJ, Sept. 17, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global surgical sealants and adhesives market is expected to grow from USD 2.08 billion in 2019 and to...
fior-markets-logo.jpg
Global Drug Discovery Outsourcing Market Is Expected to Reach USD 6.75 Billion by 2027 : Fior Markets
September 10, 2020 03:42 ET | Fior Markets
Newark, NJ, Sept. 10, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global drug discovery outsourcing market is expected to grow from USD 3.82 billion in 2019 and to...
Clear Link Between Heart Disease and COVID-19 Found by Intermountain Researchers -- Long-Term Implications Unknown
August 18, 2020 15:44 ET | Intermountain Healthcare
Salt Lake City, Utah, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Severe damage to the lungs is one of COVID-19’s most harrowing effects, making breathing hard or impossible for those who’re severely...